Dana Faber Cancer Institute Introduction to the Center for Hematology and Oncology

The Dana-Farber Cancer Institute was founded in 1947 and is a cancer specialty hospital at Harvard Medical School, a comprehensive cancer treatment and aids research center designated by the US federal government. One of the founders of the Bo / Harvard Cancer Center won the Nobel Prize for medicine.

 The Leukemia Center is globally known for its professional diagnosis and treatment of leukemia and related diseases in all stages and types. The center's transplant program is a blood and bone marrow transplant center, well-known for blood and bone marrow transplantation and approved by the Cell Therapy Foundation, which administers transplants to more than 120 patients each year.

Continuous studies such as acute lymphoblastic leukemia, acute myeloblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, hairy cell leukemia, lymphoid lymphoma, bone marrow formation, and the like: types of treatment for each central stage and leukemia, We are.

Richard M. Stone, MD 

Department: Internal Medicine 

Title: Professor of Internal Medicine at Harvard Medical School 

Inauguration Hospital: Dana Farber Cancer Institute 

Specialty: Leukemia, myelodysplastic syndrome, diagnosis and treatment of myeloproliferative diseases 

Richard M. Stone graduated from the Department of Clinical Medicine (MD) at Harvard Medical School in 1981. He was trained as a medical resident at Brigham and the Women's Hospital and completed his fellowship in Hematology and Oncology at Dana Farber Cancer Hospital. He has devoted himself to extensive clinical and basic medical research on acute leukemia and related diseases and has been asked to write a worldwide medical report.

Dr. Richard M. Stone is currently Director of the Acute Acute Leukemia Research Program at Dana Farber Cancer Hospital, a member of the Clinical Oncology Committee of the American College of Medicine and a member of the Hematology Committee. He is also the vice chair of the National Leukocyte Clinical Trials Co-Research Council. His clinical treatment and research interests focus on bone marrow stem cell disease, including acute leukemia, myeloproliferative disorders and myeloproliferative disorders.

Karen Jacobson

MD, Dana Farber, Immunology Cell Therapy Project, Medical Director 

Dr. Caron Jacobson, 

Professor Richard M. Stone and Dana Faber are doing telemedicine for outpatients. 

What is FDA approved CAR-T cell therapy?

1 Novartis: Kymriah (tisagenlecleucel) 

On August 31, 2017, the FDA approved Kymriah (tisagenlecleucel), the first gene therapy method for children and acute lymphoblastic leukemia (ALL) and young adult patients. These medicines have been approved for the treatment of cancer and other serious life-threatening new diseases. 

2 Kate Pharmaceuticals: Yescarta (axicabtagene ciloleuce)

October 18, 2017 (FDA) has received approval for a relapsed or refractory or B cell lymphoid leukemia prior to the approval of the drug Yescarta CAR-T Cell Therapy (DLBCL) for diffuse large B cell lymphoma (including axelabtagene ciloleucel with KTE-C19) ), Hodgkin's lymphoma, non-Hodgkin's lymphoma (malignant lymphoma), and primary mediastinal large B-cell lymphoma (PMBCL).

* Approved for use in non-Hodgkin lymphoma / refractory recurrent B-cell acute lymphoblastic leukemia (ALL) and submaxillary B-cell lymphoma (DLBCL) 

Yescarta Kymriah treats B cell lymphoma and leukemia cells by transforming the patient's T cell gene, the target chimeric antigen receptor, and the CD19 antigen, to express CD19 antigen targets that are expressed in a variety of tumor blood cell surface proteins. 

CAR-T Therapy Course

Patient Assessment: Patients should undergo many tests and tests to determine if CAR-T therapy is appropriate. 

T cell collection: T cells are collected separately from the patient, in which the blood is separated from the T cell by the machine and the remaining blood is returned to the patient. 

Transforming T cells: T cells are sent to the laboratory for genetic engineering to generate a chimeric antigen receptor (CAR) on the surface. CAR allows T cells to recognize antigen on the surface of tumor cells. 

T Cell Expansion: In the laboratory, genetically modified T cells continue to grow up to thousands, usually in a matter of weeks. When the CAR T cells become large enough, they are frozen and sent to the hospital where the patient is. 

T cell reperfusion: Immediately after chemotherapy, the patient was admitted to the hospital and the doctor injected CAR T cells into the body like blood transfusions. This is a one-time process, but the patient may need to stay in the hospital for several weeks to monitor the overall condition and treatment and side effects. (Before receiving a CAR T cell injection, the patient can first receive chemotherapy for cancer, which creates more room for injected CAR T cells and allows them to expand and multiply in humans.)

Recovery phase: The recovery period of CAR T treatment lasts for 2 to 3 months. In an interview with CAR T cell infusion, patients should be housed in the hospital, 1-3 weeks, while the physician monitors the response to treatment, and management of side effects appears. After the patient is discharged, regular follow-up is required over the next few months to assess side effects and response. During this period, the patient may have side effects and may be admitted again, but this is rare. 

Note: The type and severity of side effects that occur to a patient vary from person to person and there is a risk of serious complications within weeks of treatment. Generally, these complications are temporary and will follow up after consultation with your doctor. Possible side effects include cytokine release syndrome, an inflammation with symptoms such as flu (high fever / cold), but it can include not only the nervous system but also other organ dysfunctions such as hypotension and dyspnea. Problems such as confusion, difficulty understanding language, or coma. Because each patient's condition is different, the patient must communicate with the doctor in advance.